论文部分内容阅读
目的:对基础胰岛素与二肽基肽酶-4抑制剂联合治疗2型糖尿病的临床疗效进行研究探讨。方法:将2015年8月-2016年8月期间本院诊治的50例2型糖尿病患者作为研究对象,根据随机原则,将患者分成2组,25例/组。观察组采取基础胰岛素联合二肽基肽酶-4抑制剂的治疗方案,对照组则单纯给予基础胰岛素进行治疗。对比2组的空腹血糖、餐后2小时血糖、糖化血红蛋白水平及低血糖发生率。结果:与对照组相比,观察组治疗后的上述四项指标均更低(p<0.05)。结论:基础胰岛素与二肽基肽酶-4抑制剂联合治疗2型糖尿病安全有效。
Objective: To study the clinical efficacy of basal insulin and dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. Methods: Fifty patients with type 2 diabetes mellitus treated in our hospital from August 2015 to August 2016 were divided into two groups according to the randomized principle, 25 cases / group. The observation group to take basic insulin combined with dipeptidyl peptidase-4 inhibitor treatment options, the control group was treated with basal insulin alone. The fasting blood glucose, 2-hour postprandial blood glucose, HbA1c and hypoglycemia were compared between the two groups. Results: Compared with the control group, the observation group after treatment of the above four indicators were lower (p <0.05). Conclusion: The combination of basal insulin and dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes is safe and effective.